PFIZER INC PFE

Healthcare SIC 2834 - Pharmaceutical Preparations NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived NYSE

Last close 30.03 2026-10-23
Market cap $171.16B 2026-06-28 share count
52-week range 23.62 - 30.44

Valuation FY2025 figures against the last close

P/S2.7x
P/E22.1x
P/FCF18.9x
EV/EBITDA—
Dividend yield—
Diluted EPS1.36

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $62.58B$63.63B$59.55B$101.17B$73.64B$41.65B$40.91B$40.83B$52.55B$52.82B
Cost of revenue $16.07B$17.85B$24.95B$34.34B$30.82B$8.48B$8.05B$8.99B$11.23B$12.32B
Gross profit $46.51B$45.78B$34.60B$66.83B$42.81B$33.17B$32.85B$31.84B$41.32B$40.50B
SG&A $13.79B$14.73B$14.77B$13.68B$12.70B$11.60B$12.73B$12.61B$14.80B$14.84B
Interest expense $2.67B$3.09B$2.21B$1.24B$1.29B$1.45B$1.57B$1.32B$1.27B$1.19B
Pre-tax income $7.52B$8.02B$1.06B$34.73B$24.31B$7.04B$11.32B$3.59B$12.30B$8.35B
Income tax $266.0M$28.0M$1.11B$3.33B$1.85B$370.0M$583.0M$266.0M$9.05B$1.12B
Net income $7.77B$8.03B$2.12B$31.37B$21.98B$9.16B$16.03B$11.15B$21.31B$7.21B
EPS, basic 1.371.420.385.593.921.652.881.903.571.18
EPS, diluted 1.361.410.375.473.851.632.821.873.521.17
Shares, diluted (wtd. avg.) 5.71B5.70B5.71B5.73B5.71B5.63B5.67B5.98B6.06B6.16B

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $1.14B$1.04B$2.92B$468.0M$1.98B$1.82B$1.35B$1.23B$1.43B$2.67B
Short-term investments $9.18B$10.88B$4.40B$18.74B$22.01B$9.71B$6.69B$17.69B$18.65B$15.26B
Receivables $11.87B$11.46B$11.57B$10.95B$11.48B$7.91B$6.77B$8.03B$8.22B$8.22B
Inventory $10.65B$10.85B$10.19B$8.98B$9.06B$8.02B$7.07B$7.51B$7.58B$6.78B
Total current assets $42.90B$50.36B$43.33B$51.26B$59.69B$35.07B$32.80B$49.93B$41.14B$38.95B
Property, plant and equipment $19.32B$18.39B$18.94B$16.27B$14.88B$13.74B$12.97B$13.38B$13.87B$13.32B
Goodwill $71.26B$68.53B$67.78B$51.38B$49.21B$49.56B$48.18B$42.93B$55.95B$54.45B
Other intangibles $53.73B$55.41B$64.90B$43.37B$25.15B$28.34B$33.94B$35.21B$48.74B$52.65B
Total assets $208.16B$213.40B$226.50B$197.21B$181.48B$154.23B$167.59B$159.42B$171.80B$171.62B
Accounts payable $5.24B$5.63B$6.71B$6.81B$5.58B$4.28B$3.89B$4.67B$4.66B$4.54B
Short-term debt $3.00B$3.75B$2.25B$2.56B$1.64B$2.00B$1.46B$4.78B$3.55B$4.22B
Total current liabilities $36.98B$42.99B$47.79B$42.14B$42.67B$25.92B$37.30B$31.86B$30.43B$31.11B
Long-term debt $61.64B$57.41B$61.54B$32.88B$36.20B$37.13B$35.95B$32.91B$33.54B$31.40B
Total liabilities $121.39B$124.90B$137.21B$101.29B$104.01B$90.76B$104.15B$95.66B$100.14B$111.78B
Retained earnings $114.61B$116.72B$118.35B$125.66B$103.39B$90.39B$97.67B$89.55B$85.29B$71.77B
Total equity $86.48B$88.20B$89.29B$95.92B$77.46B$63.47B$63.45B$63.76B$71.66B$59.84B

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow $11.70B$12.74B$8.70B$29.27B$32.58B$14.40B$12.59B$15.83B$16.80B$16.19B
Depreciation and amortisation $6.59B$7.01B$6.29B$5.06B$5.19B$4.68B$5.75B$6.38B$6.27B$5.76B
Stock-based compensation $799.0M$877.0M$525.0M$872.0M$1.18B$755.0M$687.0M$923.0M$840.0M$691.0M
Capital expenditure $2.63B$2.91B$3.91B$3.24B$2.71B$2.23B$2.05B$1.98B$1.96B$1.82B
Investing cash flow -$1.35B$2.65B-$32.28B-$15.78B-$22.55B-$4.27B-$3.94B$4.53B-$4.74B-$7.79B
Financing cash flow -$10.30B-$17.14B$26.07B-$14.83B-$9.82B-$9.65B-$8.48B-$20.44B-$13.35B-$9.23B
Buybacks —$0$0$2.00B$0$0$8.87B$12.20B$5.00B$5.00B

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0000078003-26-000026.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. 0 50B 100B 150B Revenue, FY2016: 52.8B Gross profit, FY2016: 40.5B Net income, FY2016: 7.2B Revenue, FY2017: 52.5B Gross profit, FY2017: 41.3B Net income, FY2017: 21.3B Revenue, FY2018: 40.8B Gross profit, FY2018: 31.8B Net income, FY2018: 11.2B Revenue, FY2019: 40.9B Gross profit, FY2019: 32.9B Net income, FY2019: 16B Revenue, FY2020: 41.7B Gross profit, FY2020: 33.2B Net income, FY2020: 9.2B Revenue, FY2021: 73.6B Gross profit, FY2021: 42.8B Net income, FY2021: 22B Revenue, FY2022: 101.2B Gross profit, FY2022: 66.8B Net income, FY2022: 31.4B Revenue, FY2023: 59.6B Gross profit, FY2023: 34.6B Net income, FY2023: 2.1B Revenue, FY2024: 63.6B Gross profit, FY2024: 45.8B Net income, FY2024: 8B Revenue, FY2025: 62.6B Gross profit, FY2025: 46.5B Net income, FY2025: 7.8B FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $52.82B $52.55B $40.83B $40.91B $41.65B $73.64B $101.17B $59.55B $63.63B $62.58B
Gross profit $40.50B $41.32B $31.84B $32.85B $33.17B $42.81B $66.83B $34.60B $45.78B $46.51B
Net income $7.21B $21.31B $11.15B $16.03B $9.16B $21.98B $31.37B $2.12B $8.03B $7.77B

Recent filings and events

  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Results announced Item 2.02
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02
  • Regulation FD disclosure Item 7.01
  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Other event Item 8.01
  • Results announced Item 2.02
  • Results announced Item 2.02

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2834

TickerCompanyMarket capP/ERevenue growth
LLY ELI LILLY & Co $1.20T 55.5x 44.7%
JNJ JOHNSON & JOHNSON $635.76B 23.9x 6.0%
ABBV AbbVie Inc. $504.76B 121.0x 8.6%
MRK Merck & Co., Inc. $358.41B 20.0x 1.3%
ABT ABBOTT LABORATORIES $180.63B 27.9x 5.7%
VRTX VERTEX PHARMACEUTICALS INC / MA $132.80B 34.2x 8.9%
BMY BRISTOL MYERS SQUIBB CO $125.59B 17.8x -0.2%
REGN REGENERON PHARMACEUTICALS, INC. $82.76B 19.4x 1.0%